Literature DB >> 17401217

Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus.

S C Burjonrappa1, S Reddimasu, Z Nawaz, X Gao, P Sharma, B Loggie.   

Abstract

BACKGROUND: The molecular events that accompany the progression to adenocarcinoma (ADC) of the esophagus are poorly understood. Aberrant mucin receptor expression can contribute to increased cell growth and metastatic ability. AIM: The aim of this study was to establish a pattern for mucin (MUC) gene expression in the esophageal mucosa under normal and pathological conditions.
SETTING: University Hospital Cancer Center Laboratory. Archived tissue samples studied in a retrospective fashion.
MATERIALS AND METHODS: Tissue samples were obtained from the archives of patients with histological evidence of Barrett's esophagus (BE) progressing to ADC. Immunohistochemical analysis was performed using mouse monoclonal antibodies for MUC1, MUC2, MUC5AC, MUC6. Semiquantitative scoring of histological staining was performed using a linear scoring system: 0-staining absent; 1-staining in 0-25%; 2-staining in 25-50%; and 3-staining in 50-75% of the epithelium. The Binomial test was used to explore trends and differences in frequency of mucin expression along the pathological sequence.
RESULTS: Only mild superficial staining of MUC1 was seen in normal squamous epithelium. MUC1 and MUC2 were uniformly expressed in all samples (7/7) of BE and dysplasia (P=0.008). MUC1 expression was upregulated (7/7) in progression to adenocarcinoma (P=0.008). The secretory mucins, MUC5AC and MUC6 showed a decrease in expression with progression from BE to dysplasia to ADC (P< 0.05).
CONCLUSIONS: Downregulation of MUC5AC and MUC6 decreases mucosal protection against gastric acid. Increasing MUC1 expression is associated with progression from dysplasia to ADC. Upregulation of MUC2 reflects intestinal metaplasia in BE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401217     DOI: 10.4103/0019-509x.31160

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  9 in total

1.  The role of mucin in GERD and its complications.

Authors:  Yaron Niv; Ronnie Fass
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

2.  A relation between cell cycle and intestinal metaplasia in oesophageal biopsies using optical and digital microscopy.

Authors:  Miklós Máté; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2015-03-05       Impact factor: 3.201

3.  Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.

Authors:  Andreas Weimann; Anja Rieger; Mathias Zimmermann; Monica Gross; Peter Hoffmann; Hortense Slevogt; Lars Morawietz
Journal:  Virchows Arch       Date:  2010-09-16       Impact factor: 4.064

4.  In Vitro Modelling of Barrier Impairment Associated with Gastro-Oesophageal Reflux Disease (GERD).

Authors:  Marisa Meloni; Paolo Buratti; Francesco Carriero; Laura Ceriotti
Journal:  Clin Exp Gastroenterol       Date:  2021-09-08

5.  MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas.

Authors:  Jon M Davison; Shane T Ellis; Tyler J Foxwell; James D Luketich; Michael K Gibson; Shih-Fan Kuan; Katie S Nason
Journal:  Hum Pathol       Date:  2013-10-30       Impact factor: 3.466

6.  Expression of resistin-like molecule beta in Barrett's esophagus: a novel biomarker for metaplastic epithelium.

Authors:  Liduan Zheng; Qiangsong Tong; Mixia Weng; Jun He; Qing Lv; Zehua Wu; Zhiyong Du; Hong Mei; Xiaohua Hou
Journal:  Dig Dis Sci       Date:  2009-02-19       Impact factor: 3.199

7.  Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Derek J Nancarrow; Andrew D Clouston; B Mark Smithers; David C Gotley; Paul A Drew; David I Watson; Sonika Tyagi; Nicholas K Hayward; David C Whiteman
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

8.  Diffuse Villous Tumor Arising in Barrett's Esophagus Presenting With Aspiration Pneumonitis.

Authors:  Vishal Kaila; Nirav Thosani; Mark Feldman
Journal:  ACG Case Rep J       Date:  2019-08-27

9.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.